Takeda Pharmaceutical Company Limited;武田药品工业株式会社;武田藥品工業株式會社
发明人:
北山理乙
申请号：
MOJ001199
公开号：
MOJ001199B
申请日:
2013.09.12
申请国别(地区):
MO
年份:
2015
代理人:
摘要：
Present invention offer 1- (4- methoxybutyls)-N- (2- methyl-propyls)-N- [(3S,5R) -5- (morpholine -4- bases carbonyl) piperidines -3- bases] crystallization of -1H- benzimidazolyl-2 radicals-carboxamide hydrochloride, it is with excellent feritin inhibitory activity, and as hypertension and the prophylactic or therapeutic agent of various organ deficiencies etc. as caused by hypertension are useful. 1- (4- methoxybutyls)-N- (2- methyl-propyls)-N- [(3S,5R) -5- (morpholine -4- bases carbonyl) piperidines -3- bases] -1H- benzimidazolyl-2 radicals-carboxamide hydrochloride crystallization have powder X She Line diffraction interplanar distance (d) be 26.43±0.2,7.62±0.2 and 4.32±0.The X She Line powder diagrams at characteristic peak are shown near 2 angstroms.本發明提供1-(4-甲氧基丁基)-N-(2-甲基丙基)-N-[(3S,5R)-5-(嗎啉-4-基羰基)哌啶-3-基]-1H-苯并咪唑-2-甲酰胺鹽酸鹽的結晶，其具有優異的腎素抑制活性，且作爲高血壓和由高血壓引起的各種器官障礙等的預防劑或者治療劑有用。1-(4-甲氧基丁基)-N-(2-甲基丙基)-N-[(3S,5R)-5-(嗎啉-4-基羰基)哌啶-3-基]-1H-苯并咪唑-2-甲酰胺鹽酸鹽的結晶具有在粉末X射綫衍射的晶面間距(d)爲26.43±0.2、7.62±0.2和4.32±0.2埃附近顯示特徵峰的X射綫粉末衍射圖。
